Sandra J. Strauss
A5059920311- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- Cancer, Hypoxia, and Metabolism
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Sirtuins and Resveratrol in Medicine
- Neuroblastoma Research and Treatments
- Multiple Myeloma Research and Treatments
- PARP inhibition in cancer therapy
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- Neuroendocrine Tumor Research Advances
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Management of metastatic bone disease
- Integrated Circuits and Semiconductor Failure Analysis
- DNA Repair Mechanisms
- Gastrointestinal Tumor Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
University College London Hospitals NHS Foundation Trust
2014-2025
University College London
2016-2025
CRUK Lung Cancer Centre of Excellence
2011-2024
London Cancer
2006-2024
Royal London Hospital
2003-2024
Boehringer Ingelheim (Austria)
2023-2024
University College Hospital
2013-2023
Hudson Institute
2023
John Wiley & Sons (United States)
2023
NHS Digital
2022-2023
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European American Osteosarcoma Study (EURAMOS)-1 collaboration of four study groups aiming to improve outcomes this rare disease by facilitating randomised controlled trials.Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade in which case complete surgical resection at all sites was deemed be possible. A three-drug combination methotrexate, doxorubicin...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response preoperative (≥10% viable tumour) improved event-free survival in with high-grade osteosarcoma.EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting newly diagnosed, resectable, osteosarcoma aged 40 years or younger were eligible randomisation. Patients randomly assigned (1:1) receive either cisplatin,...
BackgroundFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as sarcoma.MethodsThe GeDDiS trial was a randomised controlled phase 3 done in 24 UK hospitals one Swiss Group Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed of Trojani grade 2 3, disease progression before enrolment, no previous chemotherapy any cancer. Patients...
Primary malignant bone sarcomas (MBS) are rare and there few studies examining their incidence outcome. Here, the survival of all subtypes MBS registered in England between 1979 2007 were analysed from patient registry data held by National Cancer Intelligence Network (NCIN). Over 11,002 new cases registered, an average 379 per year. There was no change demonstrated over study period (p = 0.08). Although a peak is observed adolescence, approximately half diagnosed patients 50 years. An...
Sequencing of cell-free DNA in the blood cancer patients (liquid biopsy) provides attractive opportunities for early diagnosis, assessment treatment response, and minimally invasive disease monitoring. To unlock liquid biopsy analysis pediatric tumors with few genetic aberrations, we introduce an integrated genetic/epigenetic method demonstrate its utility on 241 deep whole-genome sequencing profiles 95 Ewing sarcoma 31 other sarcomas. Our achieves sensitive detection classification...
Epidemiological data for sarcoma in adolescents and young adults (AYAs) across age groups are limited. We aim to: 1) update incidence, survival, changes over time European AYAs; 2) provide an updated comparison of survival AYAs versus children mature adults. calculated crude incidence rates (IR) per 100,000 population year from 2006 to 2013. Using the period approach, we 5-year relative (RS) follow-up 2010-2014. estimated bone (BS) soft tissue (STS) subtypes years 2000-2013. In AYAs, IR was...
The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen. We report the outcome a consecutive series chemonaive patients with metastatic or locally advanced treated combination 5-fluorouracil (500 mg m−2), cisplatin (70 m−2) streptozocin (1000 (FCiSt) administered three weekly up to six cycles. Patients were assessed radiological response, toxicity survival. In 79 assessable treatment FCiSt was associated an overall response rate 33% (38%...
To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response effect on plasma cytokines and vitro activity primary cultures.Patients received (1.3 mg/m2) days 1, 4, 8, 11 a 3-week cycle. Plasma tumor necrosis factor alpha (TNF-alpha) interleukin-6 were measured before each treatment, was examined patient samples grown culture.Fifty-one total 193 cycles treatment. Twenty-four had mantle cell lymphoma (MCL), 13 follicular (FL), six...
Abstract BACKGROUND: Osteosarcoma is the most common malignant bone tumor in children and young people. Efficacy of multiagent MAP (methotrexate, doxorubicin [Adriamycin], cisplatin) chemotherapy may be influenced by multiple cellular pathways. This pilot study aimed to investigate association 36 candidate genetic polymorphisms pathway genes with histological response, survival, grade 3‐4 toxicity osteosarcoma. METHODS: Blood samples were obtained from 60 patients who had completed...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase 117 lines ten types. By integrating screen with molecular profiling data, including exome sequencing show how vulnerabilities/genetic are associated mutations specific driver genes can be identified. additional sets into this analysis, protein-protein interaction also...
Undifferentiated sarcomas (USARCs) of adults are diverse, rare, and aggressive soft tissue cancers. Recent sequencing efforts have confirmed that USARCs exhibit one the highest burdens structural aberrations across human cancer. Here, we sought to unravel molecular basis complexity in by integrating DNA sequencing, ploidy analysis, gene expression, methylation profiling. We identified whole genome duplication as a prevalent pernicious force USARC tumorigenesis. Using mathematical...
Abstract Combination approaches are needed to strengthen and extend the clinical response KRAS G12C inhibitors (KRAS i). Here, we assessed antitumor responses of mutant lung colorectal cancer models combination treatment with a SOS1 inhibitor (SOS1i), BI-3406, plus inhibitor, adagrasib. We found that BI-3406 adagrasib were stronger than alone, comparable SHP2 (SHP2i) or EGFR correlated suppression RAS-MAPK signaling. also delayed emergence acquired resistance elicited from...
Purpose of review There is an unmet need to improve outcomes for patients Ewing sarcoma, a rare, aggressive sarcoma with peak incidence in adolescents and young adults (AYA). Current therapy at diagnosis involves multiagent chemotherapy local therapy, but despite intensification treatment, those metastases recurrent disease have poor outcomes. Recent findings Improved understanding biology has identified novel targets promising activity patients, including tyrosine kinase inhibitors that are...
A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in patients recurrent or refractory non-Hodgkin's lymphoma.Sixty-five were enrolled; 34 follicular lymphoma (FL), 15 diffuse large B-cell (DLBCL), 16 other lymphomas. The had received a median two prior therapies (range, 1 to 4); 23% rituximab. Epratuzumab given at 360 mg/m2 intravenously over 60 minutes followed by infusion 375 rituximab, weekly for 4 consecutive...